Trends in rheumatic disease: update on new diagnostic and treatment strategies.
Advances in our understanding of the pathophysiology of rheumatic and immunologic diseases have led to improved therapies, such as tumor necrosis factor inhibitors and bisphosphonates. These drugs can not only alleviate symptoms but also alter the course of the disease. However, they also have significant potential side effects, which mandate, more than ever, correct diagnosis and vigilant monitoring for toxicity.
Mandell
B F
BF
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, OH 44195, USA. mandelb@ccf.org
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy / Q000628:therapy; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D011111:Polymyalgia Rheumatica / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D011247:Pregnancy; D011693:Purpura / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal